RecruitingPhase 2NCT06176729

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

A Prospective Phase II Study of Polatuzumab, Rituximab, and Lenalidomide(Pola-R2) in Newly-diagnosed Non-fit Elderly DLBCL Patients

Sponsor

Yan Zhang, MD

Enrollment

30 participants

Start Date

Oct 24, 2023

Study Type

INTERVENTIONAL

Conditions

Diffuse Large B Cell Lymphoma

Summary

This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).

Eligibility

Min Age: 70 Years

Inclusion Criteria4

The patient volunteered to participate in the study and signed the Informed Consent
Histopathologically confirmed DLBCL and treatment naive(corticosteroids alone is not considered as a line of treatment)
Age≥ 70 years old, and was un-fit or frail according to comprehensive geriatric assessment
Adequate organ function and adequate bone marrow reserve

Exclusion Criteria3

Coexisting malignancy other than lymphoma
Active HBV infection
Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy